Jang Yeonsue, Kang Suki, Han Hyun Ho, Kim Baek Gil, Cho Nam Hoon
Department of Pathology, Yonsei University College of Medicine, Seoul, Republic of Korea.
Brain Korea 21 Plus Project for Medical Science, Yonsei University College of Medicine, Seoul, Republic of Korea.
Cell Death Discov. 2024 Feb 15;10(1):81. doi: 10.1038/s41420-024-01858-y.
Cancer stem-like cell (CSC) is thought to be responsible for ovarian cancer recurrence. CD24 serves as a CSC marker for ovarian cancer and regulates the expression of miRNAs, which are regulators of CSC phenotypes. Therefore, CD24-regulated miRNAs may play roles in manifesting the CSC phenotypes in ovarian cancer cells. Our miRNA transcriptome analysis showed that 94 miRNAs were up or down-regulated in a CD24-high clone from an ovarian cancer patient compared to a CD24-low one. The CD24-dependent expression trend of the top 7 upregulated miRNAs (miR-199a-3p, 34c, 199a-5p, 130a, 301a, 214, 34b*) was confirmed in other 8 clones (4 clones for each group). CD24 overexpression upregulated the expression of miR-199a-3p, 34c, 199a-5p, 130a, 301a, 214, and 34b* in TOV112D (CD24-low) cells compared to the control, while CD24 knockdown downregulated the expression of miR-199a-3p, 199a-5p, 130a, 301a, and 34b* in OV90 (CD24-high) cells. miR-130a and 301a targeted CDK19, which induced a cellular quiescence-like state (increased G0/G1 phase cell population, decreased cell proliferation, decreased colony formation, and decreased RNA synthesis) and resistance to platinum-based chemotherapeutic agents. CD24 regulated the expression of miR-130a and 301a via STAT4 and YY1 phosphorylation mediated by Src and FAK. miR-130a and 301a were positively correlated in expression with CD24 in ovarian cancer patient tissues and negatively correlated with CDK19. Our results showed that CD24 expression may induce a cellular quiescence-like state and resistance to platinum-based chemotherapeutic agents in ovarian cancer via miR-130a and 301a upregulation. CD24-miR-130a/301a-CDK19 signaling axis could be a prognostic marker for or a potential therapeutic target against ovarian cancer recurrence.
癌症干细胞样细胞(CSC)被认为是卵巢癌复发的原因。CD24作为卵巢癌的CSC标志物,并调节miRNA的表达,而miRNA是CSC表型的调节因子。因此,CD24调节的miRNA可能在卵巢癌细胞中CSC表型的表现中发挥作用。我们的miRNA转录组分析表明,与CD24低表达的克隆相比,来自一名卵巢癌患者的CD24高表达克隆中有94种miRNA上调或下调。在其他8个克隆(每组4个克隆)中证实了前7种上调miRNA(miR-199a-3p、34c、199a-5p、130a、301a、214、34b*)的CD24依赖性表达趋势。与对照相比,CD24过表达上调了TOV112D(CD24低表达)细胞中miR-199a-3p、34c、199a-5p、130a、301a、214和34b的表达,而CD24敲低下调了OV90(CD24高表达)细胞中miR-199a-3p、199a-5p、130a、301a和34b的表达。miR-130a和301a靶向CDK19,后者诱导细胞静止样状态(G0/G1期细胞群体增加、细胞增殖减少、集落形成减少和RNA合成减少)以及对铂类化疗药物的抗性。CD24通过Src和FAK介导的STAT4和YY1磷酸化调节miR-130a和301a的表达。在卵巢癌患者组织中,miR-130a和301a的表达与CD24呈正相关,与CDK19呈负相关。我们的结果表明,CD24表达可能通过上调miR-130a和301a在卵巢癌中诱导细胞静止样状态和对铂类化疗药物的抗性。CD24-miR-130a/301a-CDK19信号轴可能是卵巢癌复发的预后标志物或潜在治疗靶点。